Venous thromboembolism risk & prophylaxis in the acute hospital care setting (ENDORSE), a multinational cross-sectional study: Results from the indian subset data

Indian Journal of Medical Research

Volumn 136, Issue 1, 2012, Pages 60-67

  Pinjala, Ramakrishna ^a  

^a NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

India; Thromboprophylaxis; Venous thromboembolism(VTE); VTE risk

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPRESSION GARMENT; CROSS-SECTIONAL STUDY; DEMOGRAPHY; FEMALE; HEART FAILURE; HIP ARTHROPLASTY; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; IMMOBILIZATION; INDIA; KIDNEY DISEASE; KNEE ARTHROPLASTY; LENGTH OF STAY; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; SURGICAL PATIENT; VENOUS THROMBOEMBOLISM;

ADULT; ANTICOAGULANTS; CHEMOPREVENTION; CROSS-SECTIONAL STUDIES; FEMALE; HOSPITALIZATION; HUMANS; INDIA; INPATIENTS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84865481264     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al. For the VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe: The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-764.
2. Leizorovicz A, Cohen AT, Turpie AGG, Olsson C-G, Vaitkus PT, Goldhaber SZ. For the PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-879.
3. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al. ARTEMIS investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. BMJ 2006; 332: 325-329.
4. Leizorovicz A, Turpie AGG, Cohen AT, Wong L, Yoo MC, Dans A. For the SMART Study Group. Epidemiology of venous throboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART Study. J Thromb Haemost 2005; 3: 28-34.
5. Agarwala S, Bhagwat AS, Modhe J. Deep vein thrombosis in Indian patients undergoing major lower limb surgery. Indian JSurg 2003; 65: 159-162.
6. Parakh R, Kapadia S, Agarwal S, Grover T, Bukhari S, Yadav A, et al. Assessment of total thrombus load in symptomatic patients with venous thromboembolism. Clin Appl Thromb Hemost 2006; 12: 369-372.
7. Pinjala RK, Agarwal MB, Turpie AGG. For PROVE investigators. A Characterization of Patients with Symptomatic DVT in India. J Thromb Haemost 2005; 3 (Suppl 1), abstract no. P1043.
8. Lee AD, Stephen E, Agarwal S, Premkumar P. Venous Thrombo-embolism in India. Eur J Vasc Endovasc Surg 2009; 37: 482-485.
9. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 381S-453S.
10. Parakh R, Somaya A, Todi SK, Iyengar SS. For Consensus. Development Guidelines Panel. Consensus development recommendations for the role of LMWHs in prophylaxis of venous thromboembolism: An Indian perspective. J Assoc Physician India 2007; 55: 5-30.
11. Bergqvist D, Lindgren B, Matzsch T. Cost-effectiveness of preventing postoperative deep vein thrombosis. In: Hull RD, Pineo GF, editors. Disorders of thrombosis. Philadelphia, PA: WB Saunders; 1996. p. 228-233.
12. Bick RL. Proficient and cost-effective approaches for the prevention and treatment of venous thrombosis and thromboembolism. Drugs 2000; 60: 575-595.
13. Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, et al. For the ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008; 371: 387-394.
14. Zotz RB, Kauschat-Brüning D, Bramlage P. ENDORSE Investigators. Thromboembolic risk and prophylaxis in hospitalized surgical and internal medicine patients. German results of the international ENDORSE study. Dtsch Med Wochenschr 2009; 134: 2163-2169.
15. Dennis RJ, Roa JH, Villadiego J, Méndez F, Vieda E, Restrepo H. Venous thromboembolism prophylaxis in Colombian surgical and medical patients: results for Colombia of the ENDORSE study. Biomedica 2011; 31: 200-208.
16. Nieto Rodríguez JA. ENDORSE. Venous thromboembolism risk and antithrombotic prophylaxis among patients admitted to Spanish hospitals (ENDORSE study). Med Clin (Barc) 2009; 133: 1-7.
17. Chopard P, Spirk D, Beer HJ, Peter J, Brunner B, Bounameaux H, et al. Swiss results from a global observational study of venous thromboembolism risk and prophylaxis use in the acute care hospital setting: analysis from the ENDORSE study. Swiss Med Wkly 2009; 139: 630-635.
18. Losonczy H, Tar A; ENDORSE investigators. Results of ENDORSE study in Hungary. Multinational, cross-sectional study to assess the prevalence of venous thromboembolism risk and prophylaxis in acute hospital care setting. Orv Hetil 2008; 149: 2069-2076.
19. Bergmann JF, Cohen AT, Tapson VF, Goldhaber SZ, Kakkar AK, Deslandes B, et al. ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey. Thromb Haemost 2010; 103: 736-748.
20. Kakkar AK, Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Deslandes B, et al. ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute care hospital setting (ENDORSE survey): findings in surgical patients. Ann Surg 2010; 251: 330-338.
21. Todi SK, Sinha S, Chakraborty A, Sarkar A, Gupta S, Das T, et al. Utilization of deep venous thrombosis prophylaxis in medical/surgical intensive care units. Indian J Critical Care Med 2003; 7: 103-105.
22. Ansari K, Dalal K, Patel M. Risk stratification and utilisation of thrombo-embolism prophylaxis in a medical-surgicalICU: a hospital-based study. J Indian Med Assoc 2007; 105: 536-538, 540.
23. Mavalankar AP, Majmundar D, Rani S. Routine chemoprophylaxis for deep venous thrombosis in Indian patients: Is it really justified? Indian J Orthoped 2007; 41: 188-193.
24. Parakh R, Kakkar VV, Kakkar AK. For the Venous Thromboembolism (VTE) Core Group. Management of venous thromboembolism. J Assoc Physician India 2007;55: 49-70.
25. Agarwal S, Lee AD, Raju RS, Stephen E. Venous thromboembolism: A problem in the Indian/Asian population? Indian J Urol 2009; 25: 11-16.
26. Lindhoff-Last E, Nakov R, Misselwitz F, Breddin HK, Bauersachs R. Incidence and Clinical relevance of Heparin Induced Antibodies in patients with DVT treated with UFH or LMWH. Br J Haematol 2002; 118: 1137-1142.